BCM
CLVS

Bourgeon Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Bourgeon Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,500
Closed -$22K – 313
2020
Q4 		$22K Buy
+4,500
New +$22.8K 0.01% 184
2020
Q3 		– Sell
-11,850
Closed -$80K – 324
2020
Q2 		$80K Buy
11,850
+9,850
+493% +$74.6K 0.03% 100
2020
Q1 		$13K Buy
2,000
+250
+14% +$2K 0.01% 173
2019
Q4 		$18K Sell
1,750
-10,050
-85% -$73.1K 0.01% 157
2019
Q3 		$46K Sell
11,800
-700
-6% -$5.66K 0.02% 118
2019
Q2 		$186K Buy
+12,500
New +$226K 0.11% 68
2019
Q1 		– Sell
-12,450
Closed -$224K – 81
2018
Q4 		$224K Sell
12,450
-1,700
-12% -$34.7K 0.15% 57
2018
Q3 		$416K Buy
14,150
+800
+6% +$31K 0.21% 57
2018
Q2 		$607K Hold
13,350
– – 0.33% 50
2018
Q1 		$705K Buy
13,350
+3,600
+37% +$210K 0.39% 50
2017
Q4 		$663K Sell
9,750
-825
-8% -$57.7K 0.36% 51
2017
Q3 		$871K Buy
10,575
+1,600
+18% +$127K 0.51% 41
2017
Q2 		$840K Buy
8,975
+4,725
+111% +$289K 0.53% 39
2017
Q1 		$271K Sell
4,250
-1,000
-19% -$60.8K 0.17% 68
2016
Q4 		$233K Sell
5,250
-9,600
-65% -$338K 0.15% 77
2016
Q3 		$535K Buy
14,850
+1,000
+7% +$21.5K 0.34% 59
2016
Q2 		$190K Sell
13,850
-10,650
-43% -$156K 0.12% 83
2016
Q1 		$470K Buy
24,500
+6,350
+35% +$134K 0.31% 60
2015
Q4 		$635K Buy
+18,150
New +$1.17M 0.41% 53
2015
Q3 		– Sell
-3,150
Closed -$277K – 113
2015
Q2 		$277K Hold
3,150
– – 0.17% 93
2015
Q1 		$234K Sell
3,150
-19,600
-86% -$1.38M 0.14% 97
2014
Q4 		$1.27M Sell
22,750
-8,800
-28% -$462K 0.78% 44
2014
Q3 		$1.43M Buy
31,550
+11,450
+57% +$478K 0.83% 43
2014
Q2 		$832K Buy
+20,100
New +$1.04M 0.45% 57
2014
Q1 		– Sell
-7,500
Closed -$452K – 106
2013
Q4 		$452K Buy
+7,500
New +$408K 0.29% 72

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bourgeon Capital Management's CLVS Position: Q1 2021 in Review

Bourgeon Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q1 2021, closing a stake of 4,500 shares — an estimated $22K sold.

Bourgeon Capital Management first reported a position in CLVS in Q4 2013 and held it in 25 quarters. The position peaked at $1.43M in Q3 2014. 165 funds tracked by Wall St. Rank hold CLVS as of Q1 2021.

  • Bourgeon Capital Management reported no remaining Clovis Oncology, Inc. position as of Q1 2021 after selling out during the quarter.
  • Bourgeon Capital Management sold 4,500 Clovis Oncology, Inc. shares in Q1 2021, an estimated $22K.
  • Bourgeon Capital Management first reported a position in Clovis Oncology, Inc. in Q4 2013 and held it in 25 quarters.
  • Bourgeon Capital Management's Clovis Oncology, Inc. position peaked at $1.43M in Q3 2014.
  • 165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2021.

Based on Bourgeon Capital Management's 13F filing for Q1 2021, filed 13 May 2021.